Optimization Strategy to Minimize Wastage of Palivizumab during the 2008 RSV Season in Sao Paulo, Brazil

被引：3

作者：

Weckx, Lily Yin ^{[1
]}

Alves Fernandes, Marcia Monteiro ^{[1
]}

Melo Pereira Monteiro, Ana Isabel ^{[1
]}

Souza, Alessandra Ramos ^{[1
]}

de Moraes-Pinto, Maria Isabel ^{[1
]}

机构：

[1] Univ Fed Sao Paulo, Div Pediat Infect Dis, BR-04039032 Sao Paulo, Brazil

来源：

JOURNAL OF TROPICAL PEDIATRICS | 2009年 / 55卷 / 05期

关键词：

Palivizumab; prophylaxis; respiratory syncytial virus; RESPIRATORY SYNCYTIAL VIRUS;

D O I：

10.1093/tropej/fmp003

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab is currently recommended to high-risk children as a prophylaxis for respiratory syncytial virus (RSV) infection. However, it is still very expensive for developing countries like Brazil. Herein, we describe our strategy to minimize wastage of Palivizumab during the 2008 RSV season. Appointments were fixed for 304 children on 2 days of the week, so that a mean of 19.9 children received Palivizumab per day. That allowed remaining volumes of Palivizumab vials to be pooled and used for other children on the same day within the 6 h period after opening a vial. That strategy saved 26.3% of vials, which represents USD749 143.75.

引用

页码：341 / 342

页数：2

共 5 条

[1] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections [J].

Abramson, JS ;

Baker, CJ ;

Baltimore, RS ;

Bocchini, JA ;

Long, SS ;

McMillan, JA ;

Meissner, HC ;

Powell, KR ;

Prober, CG ;

Rennels, MB ;

Saari, TN ;

Weiner, LB ;

Blackmon, L ;

Batton, DG ;

Bell, EF ;

Denson, SE ;

Engle, WA ;

Kanto, WP ;

Martin, GI ;

Stark, AR .

PEDIATRICS, 2003, 112 (06) :1447-1452

[2] Improved outcomes with home-based administration of palivizumab - Results from the 2000-2004 Palivizumab Outcomes Registry [J].

Frogel, Michael ;

Nerwen, Cliff ;

Boron, Marnie ;

Cohen, Alan ;

VanVeldhuisen, Paul ;

Harrington, Molly ;

Groothuis, Jessie .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (10) :870-873

[3]

Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211

[4] Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus [J].

Johnson, S ;

Oliver, C ;

Prince, GA ;

Hemming, VG ;

Pfarr, DS ;

Wang, SC ;

Dormitzer, M ;

OGrady, J ;

Koenig, S ;

Tamura, JK ;

Woods, R ;

Bansal, G ;

Couchenour, D ;

Tsao, E ;

Hall, WC ;

Young, JF .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05) :1215-1224

[5]

Vieira Sandra E., 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P125, DOI 10.1590/S0036-46652001000300002

← 1 →